Codifies certain regulatory provisions regarding controlled dangerous substances and prescription monitoring.
Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances; requires reporting of xylazine prescriptions.
Controlled dangerous substances; adding exception to opioid prescription requirements.
Controlled dangerous substances; adding certain exception to prescription limits and rules for opioid drugs. Effective date.
Controlled dangerous substances; providing certain liability protections for prescription and dispensation of opioid drugs. Effective date.
Controlled dangerous substances; authorizing certain access to central repository; patient request; unsolicited notification; prescription limits. Emergency.
Expands prescription monitoring program to include veterinarians.
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.